NCT00836927View on ClinicalTrials.gov

Extension Trial of Deforolimus (Ridaforolimus, MK-8669) in Participants With Advanced Cancer (MK-8669-038)

PHASE2TerminatedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

February 1, 2009

Primary Completion Date

April 3, 2017

Study Completion Date

February 4, 2018

Conditions
Advanced Cancers
Interventions
DRUG

Ridaforolimus Tablet

Ridaforolimus 10 mg oral tablet

DRUG

Ridaforolimus Intravenous (IV) Infusion

Ridaforolimus IV infusion administered once daily for 5 days every 2 weeks in a 28-day cycle (two 2-week courses equals 1 cycle).

Sponsors

Collaborators (1)

Ariad Pharmaceuticals
All Listed Sponsors
collaborator

Ariad Pharmaceuticals

INDUSTRY

lead

Merck Sharp & Dohme LLC

INDUSTRY